^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/NRASQ61R/K/L wild-type melanoma (TraMel-WT): Interim efficacy and safety results.

Published date:
05/19/2021
Excerpt:
This two-stage, single-center phase 2 trial investigated T 2 mg QD in patients (pts) with advanced BRAFV600/NRASQ61R/K/L wt melanoma...LD-D (50 mg BID) was added to T (pre-amend)....The ORR in 14 evaluable pts is 42.9% (5 confirmed and 1 unconfirmed partial response), the disease control rate is 71.4%.
DOI:
10.1200/JCO.2021.39.15_suppl.9529
Trial ID: